Literature DB >> 26582827

Unveiling New Aspects of Meningococcal Carriage and Disease Prevention.

Magnus Gottfredsson1.   

Abstract

Recently, two protein-based vaccines have been approved for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). It is therefore important to study carefully if and how these pathogens respond to widespread vaccination. Traditionally, meningococci have been classified on the basis of capsular phenotypes, but variable levels of capsule expression can influence the results, mainly among MenB strains. In this issue, Jones and colleagues (J Clin Microbiol 54:25-34, 2016, http://dx.doi.org/10.1128/JCM.01447-15) compare whole-genome sequencing to traditional phenotypic methods of classifying meningococci. They demonstrate that for MenB in particular, sequencing-based methods are far superior to traditional methods, especially when it comes to characterizing carriage isolates. This has important implications for future surveillance.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26582827      PMCID: PMC4702742          DOI: 10.1128/JCM.02776-15

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  9 in total

1.  Comparison of Phenotypic and Genotypic Approaches to Capsule Typing of Neisseria meningitidis by Use of Invasive and Carriage Isolate Collections.

Authors:  C Hal Jones; Naglaa Mohamed; Eduardo Rojas; Lubomira Andrew; Johanna Hoyos; Julio C Hawkins; Lisa K McNeil; Qin Jiang; Leonard W Mayer; Xin Wang; Rodica Gilca; Philippe De Wals; Louise Pedneault; Joseph Eiden; Kathrin U Jansen; Annaliesa S Anderson
Journal:  J Clin Microbiol       Date:  2015-08-26       Impact factor: 5.948

2.  Molecular and serological diversity of Neisseria meningitidis carrier strains isolated from Italian students aged 14 to 22 years.

Authors:  Roberto Gasparini; Maurizio Comanducci; Daniela Amicizia; Filippo Ansaldi; Paola Canepa; Andrea Orsi; Giancarlo Icardi; Emanuela Rizzitelli; Gabriella De Angelis; Stefania Bambini; Monica Moschioni; Sara Comandi; Isabella Simmini; Giueseppe Boccadifuoco; Brunella Brunelli; Marzia Monica Giuliani; Mariagrazia Pizza; Donatella Panatto
Journal:  J Clin Microbiol       Date:  2014-03-19       Impact factor: 5.948

3.  Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial.

Authors:  Robert C Read; David Baxter; David R Chadwick; Saul N Faust; Adam Finn; Stephen B Gordon; Paul T Heath; David J M Lewis; Andrew J Pollard; David P J Turner; Rohit Bazaz; Amitava Ganguli; Tom Havelock; Keith R Neal; Ifeanyichukwu O Okike; Begonia Morales-Aza; Kamlesh Patel; Matthew D Snape; John Williams; Stefanie Gilchrist; Steve J Gray; Martin C J Maiden; Daniela Toneatto; Huajun Wang; Maggie McCarthy; Peter M Dull; Ray Borrow
Journal:  Lancet       Date:  2014-08-18       Impact factor: 79.321

4.  Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis.

Authors:  J Finne; M Leinonen; P H Mäkelä
Journal:  Lancet       Date:  1983-08-13       Impact factor: 79.321

5.  Predicted strain coverage of a meningococcal multicomponent vaccine (4CMenB) in Europe: a qualitative and quantitative assessment.

Authors:  Ulrich Vogel; Muhamed-Kheir Taha; Julio A Vazquez; Jamie Findlow; Heike Claus; Paola Stefanelli; Dominique A Caugant; Paula Kriz; Raquel Abad; Stefania Bambini; Anna Carannante; Ala Eddine Deghmane; Cecilia Fazio; Matthias Frosch; Giacomo Frosi; Stefanie Gilchrist; Marzia M Giuliani; Eva Hong; Morgan Ledroit; Pietro G Lovaglio; Jay Lucidarme; Martin Musilek; Alessandro Muzzi; Jan Oksnes; Fabio Rigat; Luca Orlandi; Maria Stella; Danielle Thompson; Mariagrazia Pizza; Rino Rappuoli; Davide Serruto; Maurizio Comanducci; Giuseppe Boccadifuoco; John J Donnelly; Duccio Medini; Ray Borrow
Journal:  Lancet Infect Dis       Date:  2013-02-13       Impact factor: 25.071

6.  Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing.

Authors:  M Pizza; V Scarlato; V Masignani; M M Giuliani; B Aricò; M Comanducci; G T Jennings; L Baldi; E Bartolini; B Capecchi; C L Galeotti; E Luzzi; R Manetti; E Marchetti; M Mora; S Nuti; G Ratti; L Santini; S Savino; M Scarselli; E Storni; P Zuo; M Broeker; E Hundt; B Knapp; E Blair; T Mason; H Tettelin; D W Hood; A C Jeffries; N J Saunders; D M Granoff; J C Venter; E R Moxon; G Grandi; R Rappuoli
Journal:  Science       Date:  2000-03-10       Impact factor: 47.728

7.  Use of Serogroup B Meningococcal Vaccines in Adolescents and Young Adults: Recommendations of the Advisory Committee on Immunization Practices, 2015.

Authors:  Jessica R MacNeil; Lorry Rubin; Temitope Folaranmi; Ismael R Ortega-Sanchez; Manisha Patel; Stacey W Martin
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-10-23       Impact factor: 17.586

8.  Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections.

Authors:  Magnus Gottfredsson; Ingi K Reynisson; Ragnar F Ingvarsson; Hafrun Kristjansdottir; Martina V Nardini; Jon F Sigurdsson; Rachel Schneerson; John B Robbins; Mark A Miller
Journal:  Clin Infect Dis       Date:  2011-09-26       Impact factor: 9.079

9.  Genomic epidemiology of age-associated meningococcal lineages in national surveillance: an observational cohort study.

Authors:  Dorothea M C Hill; Jay Lucidarme; Stephen J Gray; Lynne S Newbold; Roisin Ure; Carina Brehony; Odile B Harrison; James E Bray; Keith A Jolley; Holly B Bratcher; Julian Parkhill; Christoph M Tang; Ray Borrow; Martin C J Maiden
Journal:  Lancet Infect Dis       Date:  2015-10-27       Impact factor: 25.071

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.